Evaluating Value-Anchored Price Ranges for Desmoid Tumor Therapies

Last updated Jul 27, 2026

TL/DR –

The Center for Pharmacoeconomics has estimated the value-anchored price ranges for desmoid tumor therapies based on their implied reimbursement value and potential health economic value. The report provides efficacy-dependent price ranges for new desmoid tumor therapies, and allows biotech executives and investors to benchmark their pricing assumptions against these ranges. These price ranges should be seen as quantitative reference points, not predictions of future market prices, as actual market prices will reflect factors such as competition, payer negotiations, health policy, and broader market dynamics.

Pharmacoeconomic Evaluation of Desmoid Tumor Therapies

Our Center for Pharmacoeconomics Spotlight presents a comprehensive analysis of desmoid tumor therapies, providing value-anchored price ranges. We have determined these ranges based on implied reimbursement value and potential health economic value. The full report delves into:

Estimating the US market’s willingness to pay for health enhancements, considering the reimbursement of an approved desmoid tumor treatment.
Comparing the implied reimbursement value threshold with thresholds based on the health economic proposition for a desmoid tumor therapy.
Supplying efficacy-dependent price ranges based on the implied reimbursement value and potential health economic value for new desmoid tumor treatments.

Biotech executives and investors can use these ranges to benchmark their pricing assumptions against the therapy’s pharmacoeconomic profile. The price ranges should serve as quantitative reference points, not future market price predictions, and reflect the current reimbursement patterns and health economic methods within the analytical framework. Market prices will continue to change due to factors like competition, payer negotiations, health policy, and broader market dynamics.

For full access to the report, contact us via email at cpe@medacorp.com.

Disclosures

The Center for Pharmacoeconomics is a division of MEDACorp LLC. The Center supports decisions intended to improve societal outcomes and provides information for the sole use of the recipient, without constituting investment or other advice. Information sources are believed to be reliable, though accuracy or completeness is not guaranteed and may change without notice. Opinions and information are current as of the date of this material, with no obligation to update. This document may not be reproduced, edited, or circulated without MEDACorp’s express written consent.

—
Read More Health & Wellness News ; US News